Potent anti-cancer agents

Despite advances in immuno-oncology, many solid tumors remain stubbornly difficult to treat. Aktis is developing a pipeline of multiple precision engineered targeting molecules to deliver the curative power of alpha radiotherapy to a range of cancers including breast, lung, colorectal, bladder, and liver cancers.

282K

new cases of
breast cancer in
US annually

235K

new cases of lung
cancer in US
annually

149K

new cases of
colorectal cancer
in US annually

84K

new cases of
bladder cancer in
US annually

42K

new cases of liver
cancer in US
annually

A pipeline of targeting molecules

Our current proprietary pipeline is comprised of seven programs, including our clinical-stage program targeting Nectin-4. We look forward to sharing more information as the programs advance.

Partner with us

Interested in bringing alpha radiotherapy to the mainstream? Contact us for information about corporate partnership opportunities.

Contact Us
Scientist in lab coat holding a test tube and beaker